GT Biopharma, Inc. (GTBP)
6.68
+0.72
(+12.08%)
USD |
NASDAQ |
Oct 09, 16:00
6.79
+0.11
(+1.65%)
After-Hours: 20:00
GT Biopharma Net Income (Quarterly) : -4.518M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.518M |
| March 31, 2026 | -2.833M |
| December 31, 2025 | -23.03M |
| September 30, 2025 | 8.299M |
| June 30, 2025 | -30.17M |
| March 31, 2025 | -0.776M |
| December 31, 2024 | -3.775M |
| September 30, 2024 | -3.411M |
| June 30, 2024 | -3.71M |
| March 31, 2024 | -2.266M |
| December 31, 2023 | -2.962M |
| September 30, 2023 | -2.416M |
| June 30, 2023 | -1.992M |
| March 31, 2023 | -0.227M |
| December 31, 2022 | -5.584M |
| September 30, 2022 | -6.881M |
| June 30, 2022 | -2.979M |
| March 31, 2022 | -5.44M |
| December 31, 2021 | -18.02M |
| September 30, 2021 | -5.453M |
| June 30, 2021 | -4.861M |
| March 31, 2021 | -29.68M |
| December 31, 2020 | -14.93M |
| September 30, 2020 | -2.876M |
| June 30, 2020 | -17.42M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.708M |
| December 31, 2019 | -1.47M |
| September 30, 2019 | -29.88M |
| June 30, 2019 | -2.789M |
| March 31, 2019 | -4.51M |
| December 31, 2018 | -4.231M |
| September 30, 2018 | -235.78M |
| June 30, 2018 | -9.081M |
| March 31, 2018 | -10.09M |
| December 31, 2017 | -6.026M |
| September 30, 2017 | -130.62M |
| June 30, 2017 | -2.463M |
| March 31, 2017 | -5.058M |
| December 31, 2016 | -2.829M |
| September 30, 2016 | -3.63M |
| June 30, 2016 | 1.543M |
| March 31, 2016 | 14.68M |
| December 31, 2015 | -26.11M |
| September 30, 2015 | -1.692M |
| June 30, 2015 | 26.86M |
| March 31, 2015 | -20.52M |
| December 31, 2014 | -18.66M |
| September 30, 2014 | -4.219M |
| June 30, 2014 | -0.261M |
| March 31, 2014 | -0.37M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 4.518M |
| EPS Diluted (Quarterly) | -2.957 |
| Enterprise Value | 6.883M |
| Earnings Yield | -1.35K% |
| Normalized Earnings Yield | -2579.14 |